Brokerages Set AcelRx Pharmaceuticals Inc (ACRX) Target Price at $9.80

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has been assigned an average rating of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $9.80.

Several equities research analysts have recently weighed in on the company. Roth Capital set a $15.00 price objective on AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, March 6th. Cowen and Company reissued a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Monday, March 6th. Royal Bank of Canada reissued an “outperform” rating and set a $6.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Friday, March 3rd. Zacks Investment Research lowered AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Finally, Stifel Nicolaus reduced their price objective on AcelRx Pharmaceuticals from $15.00 to $14.00 and set a “hold” rating for the company in a research note on Tuesday, March 14th.

Hedge funds have recently added to or reduced their stakes in the stock. State Street Corp raised its stake in AcelRx Pharmaceuticals by 2.4% in the fourth quarter. State Street Corp now owns 487,777 shares of the specialty pharmaceutical company’s stock worth $1,268,000 after buying an additional 11,639 shares during the last quarter. Oxford Asset Management raised its stake in shares of AcelRx Pharmaceuticals by 48.7% in the fourth quarter. Oxford Asset Management now owns 103,420 shares of the specialty pharmaceutical company’s stock valued at $269,000 after buying an additional 33,866 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in shares of AcelRx Pharmaceuticals during the fourth quarter valued at about $14,063,000. Teachers Advisors LLC raised its stake in shares of AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 8,475 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 32,087 shares in the last quarter. Institutional investors own 30.28% of the company’s stock.

AcelRx Pharmaceuticals (NASDAQ ACRX) traded up 4.35% during trading on Tuesday, hitting $2.40. The stock had a trading volume of 297,061 shares. AcelRx Pharmaceuticals has a 1-year low of $1.95 and a 1-year high of $4.08. The stock’s market cap is $108.91 million. The firm’s 50-day moving average price is $2.52 and its 200-day moving average price is $2.80.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings data on Monday, May 8th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.06. The firm had revenue of $3.11 million during the quarter, compared to analyst estimates of $2.36 million. On average, equities research analysts predict that AcelRx Pharmaceuticals will post ($1.10) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first posted by sleekmoney and is owned by of sleekmoney. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://sleekmoney.com/brokerages-set-acelrx-pharmaceuticals-inc-acrx-target-price-at-9-80/1916671.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/brokerages-set-acelrx-pharmaceuticals-inc-acrx-target-price-at-9-80/1916671.html

Receive News & Ratings for AcelRx Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *